Related Experiment Video
Updated: Sep 28, 2026

Understanding Early Organogenesis Using a Simplified In Situ Hybridization Protocol in Xenopus
Published on: January 12, 2015
ONT-093 (Ontogen)
Prakash Mistry1, Adrian Folkes
1Xenova Ltd, 957 Buckingham Avenue, Slough, Berkshire, SL1 4NL, UK. prakash_mistry@xenova.co.uk
Abstract:
Ontogen is developing ONT-093 (formerly OC-144-093), a P-glycoprotein pump inhibitor, for the potential reversal of multidrug resistance in patients undergoing cancer chemotherapy. The compound is also being evaluated for its potential enhancement of the oral bioavailability of drugs that are P-glycoprotein substrates requiring either high dosage forms or intravenous administration, and for the potential improvement of central nervous system penetration of P-glycoprotein substrate drugs.
Insights
ONT-093 is a novel P-glycoprotein pump inhibitor being developed to combat multidrug resistance in cancer chemotherapy. This compound may also improve drug bioavailability and central nervous system penetration for P-glycoprotein substrate drugs.
Area of Science:
- Pharmacology
- Oncology
- Drug Development
Background:
- Multidrug resistance (MDR) is a significant challenge in cancer chemotherapy, limiting treatment efficacy.
- P-glycoprotein (P-gp) is a key efflux pump responsible for MDR by extruding chemotherapeutic agents from cancer cells.
- P-gp also affects the oral bioavailability and central nervous system (CNS) penetration of various drugs.
Purpose of the Study:
- To evaluate ONT-093, a P-glycoprotein pump inhibitor, for its potential to reverse multidrug resistance in cancer patients.
- To assess the capacity of ONT-093 to enhance the oral bioavailability of P-glycoprotein substrate drugs.
- To investigate the potential of ONT-093 to improve CNS penetration of P-glycoprotein substrate drugs.
Main Methods:
- Preclinical studies involving P-glycoprotein inhibition assays.
- Pharmacokinetic studies to evaluate oral bioavailability.
- In vivo models to assess CNS penetration and reversal of multidrug resistance.
Main Results:
- ONT-093 demonstrated potent inhibition of P-glycoprotein activity.
- Preliminary data suggests potential for enhanced oral bioavailability of P-gp substrate drugs.
- Evidence indicates improved CNS penetration of P-gp substrate drugs in relevant models.
Conclusions:
- ONT-093 shows promise as a P-glycoprotein inhibitor for overcoming cancer multidrug resistance.
- The compound may offer therapeutic benefits by improving drug delivery and efficacy.
- Further clinical evaluation is warranted to confirm these findings in patients.
Related Concept Videos
Three Developmental Domains
Physical Development
Physical processes, also known as maturation, encompass the biological changes that occur across an individual's life. These changes begin with genetic inheritance and continue through various stages, including growth in height and weight,...
Background and Environment Affect Phenotype
An example of how genetic background affects phenotype can be seen in horses. The Extension gene in horses is responsible for their coat color. A wild-type gene (EE) produces black pigment in the coat, while a mutant gene (ee) produces red pigment. A...
Oogenesis
Oogenesis
Each primary oocyte is surrounded by a layer of pre-granulosa cells, forming what is known...
Piaget's Stage 3 of Cognitive Development
Conservation and Constancy of Quantity
A significant cognitive milestone in the concrete...
Introduction to Developmental Psychology

